 |
4 Products |  |
41 Diseases | | 4 Products |
|
152 Trials |  |
6863 News |  |
| 12345678910111213...8889» |
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF. (Pubmed Central) - Nov 20, 2024
P3
Sacubitril/valsartan may be more effective than enalapril in reducing the risk of death in patients not treated with a beta-blocker compared to those treated with a beta-blocker, but is effective regardless of beta-blocker use.
- |||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
New trial, Real-world evidence, Real-world: ROVER Japan: An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan (clinicaltrials.gov) - Nov 20, 2024
P=N/A, N=7000, Not yet recruiting, Sponsor: Bayer
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Efficacy of Sacubitril/Valsartan in a Patient With Heart Failure and Impaired Secretion of Atrial Natriuretic Peptide Due to Long-Standing Persistent Atrial Fibrillation. (Pubmed Central) - Nov 19, 2024
This case highlights the possibility of impaired ANP secretion in response to volume overload as a predictor of the diuretic effect of sacubitril/valsartan in heart failure. This may lead to individualized treatment for each patient with heart failure based on natriuretic peptide profiles.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
New P3 trial: A Study of Entresto in Tetralogy of Fallot (TOF) and Ebstein's Anomaly (EA) (clinicaltrials.gov) - Nov 17, 2024
P3, N=45, Not yet recruiting, Sponsor: Mayo Clinic
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Enhancing ventricular remodeling and cardiac function in post-acute myocardial infarction with sacubitril/valsartan. (Pubmed Central) - Nov 17, 2024
P=N/A
Our findings indicate that sacubitril/valsartan (LCZ696) Sodium Tablets effectively enhance ventricular remodeling and cardiac function in patients with HF post-AMI, following a short-term treatment regimen. This therapeutic approach holds promise for improving clinical outcomes in this patient population.
- || Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Retrospective data, Review, Journal: Efficacy of Sarcupyrine/valsartan in the treatment of acute myocardial infarction: a meta-analysis. (Pubmed Central) - Nov 17, 2024
This therapeutic approach holds promise for improving clinical outcomes in this patient population. Sacubitril/Valsartan improves cardiac function in patients with AMI, reduces the risk of postoperative myocardial reinfarction, and reduces the risk of hospitalization for HF.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Addition of Sacubitril/Valsartan to Mineralocorticoid Receptor Antagonist Therapy in Primary Aldosteronism: Effects on Plasma Aldosterone Concentration and Plasma Renin Activity. (Pubmed Central) - Nov 17, 2024
The pathological significance of the phenomenon whereby PAC increases with MRA administration but decreases with the addition of sacubitril/valsartan is unclear. In PA, more effective treatment may be possible by suppressing aldosterone with sacubitril/valsartan and blocking the action of aldosterone with MRAs.
- || Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Review, Journal: Cross talk on therapeutic strategies: natriuretic peptides and inhibiting neprilysin in hypertension management. (Pubmed Central) - Nov 17, 2024
Valsartan/sacubitril (ARNi), marketed as Entresto by Novartis, combines valsartan, an angiotensin receptor blocker, with sacubitril, an inhibitor of neprilysin...Schematic representation of the mechanism of action of ARNi. Abbreviation: -Renin angiotensin aldosterone system (RAAS), Natriuretic peptides (NP), Atrial Natriuretic peptide (ANP), Brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), Angiotensin II (Ang II), Angiotensin receptor neprilysin inhibitor (ARNI).
- | Minnebro (esaxerenone) / Daiichi Sankyo, Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal, Surgery: Determining optimal pretreatment in cardiac surgery: an experimental study. (Pubmed Central) - Nov 16, 2024
Abbreviation: -Renin angiotensin aldosterone system (RAAS), Natriuretic peptides (NP), Atrial Natriuretic peptide (ANP), Brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), Angiotensin II (Ang II), Angiotensin receptor neprilysin inhibitor (ARNI). Oral administration of esaxerenone or sacubitril/valsartan to rats 2
- || Enblo (enavogliflozin) / Daewoong Pharma, GC Biopharma, M8 Pharma
Trial completion date, Trial primary completion date: ARNI-TAVI: ENAVOgliflozin Outcome Trial in Patients with Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (clinicaltrials.gov) - Nov 15, 2024
P4, N=1040, Not yet recruiting, Sponsor: Duk-Woo Park, MD
Oral administration of esaxerenone or sacubitril/valsartan to rats 2 Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
- || Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Clinical, Journal: Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MI. (Pubmed Central) - Nov 14, 2024
Following acute MI, patients assigned to sacubitril/valsartan had a higher frequency of initial increases in serum creatinine at 1?week, compared with ramipril. In adjusted models, initial increases in serum creatinine with either treatment were not associated with adverse cardiovascular outcomes or changes in longer-term kidney function.
- || Clinical, Retrospective data, Review, Journal: A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients. (Pubmed Central) - Nov 13, 2024
In adjusted models, initial increases in serum creatinine with either treatment were not associated with adverse cardiovascular outcomes or changes in longer-term kidney function. AZL-M at 40
- || Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Review, Journal: Angiotensin Receptor-Neprilysin Inhibitor for Chronic Kidney Disease: Strategies for Renal Protection. (Pubmed Central) - Nov 13, 2024
Evidence supporting the renal benefits of ARNI continues to evolve; therefore, ARNI could mitigate renal dysfunction in select patient populations. Further research should be performed to clarify the efficacy of ARNI for advanced renal failure and refine its therapeutic application for patients with concurrent HF and renal dysfunction.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Preclinical, Journal: Sacubitril/valsartan alleviates myocardial infarction-induced inflammation in mice by promoting M2 macrophage polarisation via regulation of PI3K/Akt pathway. (Pubmed Central) - Nov 13, 2024
Blocking PI3K/Akt signalling counteracted Sac/Val-mediated protective effects in MI mice. Sac/Val ameliorates MI-induced inflammation by facilitating M2 macrophage polarisation and activating PI3K/Akt signalling.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial. (Pubmed Central) - Nov 13, 2024
P4
In-hospital Sac/Val therapy initiation in addition to contemporary recommended therapy triggered a greater NT-proBNP level reduction in Japanese patients hospitalized for AHF. These findings may expand the evidence on Sac/Val therapy in this clinical situation outside North America.
- || Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Clinical, Retrospective data, Journal: Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials. (Pubmed Central) - Nov 13, 2024
P3
This reduction appeared to be principally driven by lower rates of cardiac and pulmonary hospitalizations. ClinicalTrials.gov Identifiers: NCT01035255 (PARADIGM-HF) and NCT01920711 (PARAGON-HF).
- | Contrave (naltrexone/bupropion) / Currax
Trial completion, Trial completion date: Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study (clinicaltrials.gov) - Nov 12, 2024
P2, N=55, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ClinicalTrials.gov Identifiers: NCT01035255 (PARADIGM-HF) and NCT01920711 (PARAGON-HF). Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2024
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
New trial: Efficacy and safety of Sacubitril/Valsartan in improving collateral circulation in hypertensive patients with acute ischemic stroke (EUDRACT) - Nov 10, 2024
P=N/A, N=92, Completed, Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
New P4 trial: A prospective study on the effect of Sacubitril Valsartan Sodium in treatment of type 2 diabetes mellitus complicated with hypertension on insulin resistance (EUDRACT) - Nov 10, 2024
P4, N=120, Not yet recruiting, Sponsor: Armed Police Hospital of Chongqing; Armed Police Hospital of Chongqing
- || Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Review, Journal: Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India. (Pubmed Central) - Nov 6, 2024
The document underwent scrutiny by expert cardiologists, whose clinical experiences and examination of the evidence and guidelines informed the formation of the expert opinion. This expert opinion paper provides a thorough and informed evaluation of sacubitril/valsartan, highlighting its potential to address unmet needs in BP control, particularly in challenging cases such as resistant hypertension and chronic kidney disease.
- || Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Clinical data, Journal: Characteristics, Predictors, and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction According to a 1-Year Left Ventricular Ejection Fraction Following Sacubitril/Valsartan Treatment. (Pubmed Central) - Nov 5, 2024
This expert opinion paper provides a thorough and informed evaluation of sacubitril/valsartan, highlighting its potential to address unmet needs in BP control, particularly in challenging cases such as resistant hypertension and chronic kidney disease. Patients with HFimpEF had better prognosis than those with perHFrEF, and ARNI treatment in HFrEF could be more beneficial than renin-angiotensin-aldosterone system inhibitors for both HFimpEF and perHFrEF.
- Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Utilization and Expenditure on Sacubitril/Valsartan (Entresto () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2849;
Patients with HFimpEF had better prognosis than those with perHFrEF, and ARNI treatment in HFrEF could be more beneficial than renin-angiotensin-aldosterone system inhibitors for both HFimpEF and perHFrEF. The RAS for Entresto
- Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Cost-Effectiveness Analysis of Sacubitril/Valsartan in Heart Failure Patients in Egypt () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2198;
Sacubitril/valsartan compared to SOC lead to improved outcomes in HF patients. It is considered as a cost-effective treatment compared to SOC in HFrEF patients and represents as a good value for the patients, caregivers, society and economy.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Trial completion date: Heart Failure Polypill at a Safety Net Hospital (clinicaltrials.gov) - Nov 4, 2024
P2, N=35, Active, not recruiting, Sponsor: University of California, San Francisco
It is considered as a cost-effective treatment compared to SOC in HFrEF patients and represents as a good value for the patients, caregivers, society and economy. Trial completion date: Sep 2024 --> Dec 2024
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Status and timing of angiotensin receptor-neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry. (Pubmed Central) - Nov 3, 2024
ARNI were more likely initiated in patients with more severe HF, which might suggest its use as a second-line treatment and only following worsening of clinical status. One-year discontinuation rates were consistent regardless of the timing/setting of ARNI initiation.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Enrollment open, Trial completion date, Trial primary completion date: CRACOVIA-HF: The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction (clinicaltrials.gov) - Oct 31, 2024
P3, N=666, Recruiting, Sponsor: John Paul II Hospital, Krakow
One-year discontinuation rates were consistent regardless of the timing/setting of ARNI initiation. Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Mar 2027
- || Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Retrospective data, Review, Journal: The in-hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta-analysis. (Pubmed Central) - Oct 30, 2024
Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Mar 2027 Higher rates of iatrogenic hypotensive events were observed in the ARNi group compared with the standard therapy (OR 1.42, 95% CI 1.26-1.60, P value
- || Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Retrospective data, Review, Journal: Sacubitril-Valsartan Lowers Atrial Fibrillation Recurrence and Left Atrial Volume Post-catheter Ablation: Systematic Review and Meta-Analysis. (Pubmed Central) - Oct 29, 2024
SV therapy exhibited superior efficacy in reducing AF recurrence compared with ACEi or ARB and demonstrated superior outcomes in attenuating atrial structural remodeling after catheter ablation. These findings underscore the potential of SV as a therapeutic option for patients with AF undergoing catheter ablation, highlighting its efficacy in mitigating AF recurrence and structural remodeling.
- |||||| Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
New trial: Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure) (clinicaltrials.gov) - Oct 28, 2024
P=N/A, N=33, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Angiotensin receptor-neprilysin inhibition and improved ventricular-arterial coupling in heart failure with reduced ejection fraction. (Pubmed Central) - Oct 25, 2024
In conclusion, sacubitril/valsartan is associated with improved ventricular-arterial coupling by enhancing LV contractility and reducing afterload. Beyond LV reverse remodeling, optimized ventricular-arterial interaction may contribute to the favorable outcome of sacubitril/valsartan treatment in HF with reduced EF.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Preclinical, Journal: Sacubitril/valsartan improves diastolic left ventricular stiffness with increased titin phosphorylation via cGMP-PKG activation in diabetic mice. (Pubmed Central) - Oct 24, 2024
The phosphorylation level of titin (N2B), which determines passive stiffness and modulates active contraction, was higher in Sac/Val-treated hearts compared with Val-treated hearts in diabetic mice. Given that alteration of titin phosphorylation through PKG contributes to myocardial stiffness, the beneficial effects of Sac/Val in heart failure might be partly attributed to the induction of titin phosphorylation.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart (Pubmed Central) - Oct 23, 2024
Given that alteration of titin phosphorylation through PKG contributes to myocardial stiffness, the beneficial effects of Sac/Val in heart failure might be partly attributed to the induction of titin phosphorylation. Although both asymptomatic and symptomatic hypotension during treatment with sacubitril/valsartan or enalapril were associated with worse outcomes, the benefits of sacubitril/valsartan were maintained (or even enhanced) in patients experiencing hypotension.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trials. (Pubmed Central) - Oct 23, 2024
P3
The detection of notable increases in HR between outpatient visits may help identify patients at heightened risk of adverse events. Clinical Trial Registration; ClinicalTrials.gov NCT01035255 (PARADIGM-HF), NCT01920711 (PARAGON-HF).
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
New P2 trial, Combination therapy, Metastases: Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF (clinicaltrials.gov) - Oct 22, 2024
P2, N=50, Not yet recruiting, Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- || Clinical, Retrospective data, Review, Journal: Efficacy of modern therapies for heart failure with reduced ejection fraction in specific population subgroups: a systematic review and network meta-analysis. (Pubmed Central) - Oct 22, 2024
Clinical Trial Registration; ClinicalTrials.gov NCT01035255 (PARADIGM-HF), NCT01920711 (PARAGON-HF). Emerging HFrEF therapies show a clinical benefit with the reduction of the primary composite endpoint of CVD and HFH, with each drug being more effective in specific patient population.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. (Pubmed Central) - Oct 21, 2024
In patients with heart failure and preserved ejection fraction, even modest baseline impairment of cognitive function was associated with worse outcomes, including death. A decline in MMSE score during follow-up was a strong predictor of mortality, independent of other prognostic variables.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Potential Effects of Sacubitril/Valsartan on the Cardio-ankle Vascular Index in Hypertensive Patients. (Pubmed Central) - Oct 21, 2024
Results The systolic blood pressure (BP), diastolic BP, and CAVI were significantly decreased by ARNI administration (systolic BP: 145 [135, 162] to 131 [123, 143] mmHg [p=0.000]; diastolic BP: 92 [78, 100] to 82 [74, 89] mmHg [p=0.000]; and CAVI: 9.9 [9.1, 10.5] to 9.5 [8.8, 10.2] mmHg [p=0.005], respectively). Conclusion Hypertension treatment with ARNIs may improve not only the blood pressure but also the CAVI, reducing the afterload on the heart.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Sacubitril/Valsartan: A Game-Changer for Hypertensive Patients Beyond Blood Pressure Control? (Pubmed Central) - Oct 21, 2024
Conclusion Hypertension treatment with ARNIs may improve not only the blood pressure but also the CAVI, reducing the afterload on the heart. No abstract available
- Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical protocol, Journal: Rationale and design of Dapagliflozin vErsus SacubiTrIl-valsartaN therapY in Heart Failure with reduced ejection fraction (DESTINY-HF): a pragmatic randomised controlled trial protocol. (Pubmed Central) - Oct 19, 2024
The study aims to provide clinicians with data to make informed decisions regarding the preferred drug class. Additionally, examining the impact of ARNI and SGLT2i on GDF-15 levels could offer better insights into prognosis among patients with HFrEF.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Preclinical, Journal: Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction. (Pubmed Central) - Oct 19, 2024
In conclusion, SAC/VAL treatment improved diastolic and hepatic function, respiratory metabolism, reduced hypercholesterolemia and cardiac fibrosis and hypertrophy, and was able to modulate cardiac metabolic profile. Our findings might provide further insight into the therapeutic benefits of SAC/VAL treatment in obese patients with HFpEF.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: The ventilatory efficiency parameters outperform peak oxygen consumption in monitoring the therapy effects in patients with hypertrophic cardiomyopathy. (Pubmed Central) - Oct 19, 2024
Our findings might provide further insight into the therapeutic benefits of SAC/VAL treatment in obese patients with HFpEF. Ventilatory efficiency parameters outperform peak VO2 in gauging therapy effects in patients with HCM.
- || Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories
Review, Journal: Risperidone ISM (Pubmed Central) - Oct 18, 2024
Improvement and maintenance of personal and social functioning and health-related quality of life were observed in each setting, respectively. All these findings endorse Risperidone ISM as a useful and valuable treatment for the acute and maintenance management of patients with schizophrenia.
- || Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Simdax (levosimendan IV) / AbbVie
Retrospective data, Review, Journal: Meta-analysis of a controlled study of levosimendan combined with Sacubitril/Valsartan for the treatment of heart failure with reduced ejection fraction in China. (Pubmed Central) - Oct 18, 2024
Meta-analysis results showed that levosimendan combined with Sacubitril/Valsartan has a better therapeutic effect on heart failure with reduced ejection fraction and is beneficial for improving cardiac function. The main mechanism for this may be related to the pharmacological action of levosimendan.
- | Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories
Journal: Exposure-Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM. (Pubmed Central) - Oct 17, 2024
Pharmacokinetic/pharmacodynamic modeling quantified a PANSS improvement over time after Risperidone ISM administration. The response was not significantly different in either dose group, likely because D2RO was already above the proposed efficacy threshold (65%) within 1 h after the first Risperidone ISM injection and remained above this level following repeated administrations.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Preclinical, Journal: Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through ?-AR Responsiveness in a Rat Model of Type 2 Diabetes. (Pubmed Central) - Oct 16, 2024
?3-AR-mediated cardiac relaxation (an indicator of diastolic function) responses were comparable among groups. The beneficial effect of sacubitril/valsartan on systolic function may be attributed to improved ?1-/?2-AR responsiveness.
- |||||||||| Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
New P3 trial: Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A (clinicaltrials.gov) - Oct 16, 2024
P3, N=324, Not yet recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- || Contrave (naltrexone/bupropion) / Currax, Mounjaro (tirzepatide) / Eli Lilly
Review, Journal: Tackling Cravings in Medical Weight Management: An Update on Pathophysiology and an Integrated Approach to Treatment. (Pubmed Central) - Oct 16, 2024
Finally, based on these findings, we provide a proposed integrated and iterative model that is able to evolve and adapt to the individual over time in tackling cravings for long-term weight loss maintenance. The findings emphasise the importance of cravings management and provide a synthesis on how cravings can be identified in a medical weight management setting, which can be practically implemented in an integrated iterative model spanning anti-obesity medications that have craving control data to evidence-based lifestyle and psychological interventions.
- || Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Review, Journal: Advances in pharmacotherapy for heart failure and reduced ejection fraction: what's new in 2024? (Pubmed Central) - Oct 16, 2024
These developments underscore a dynamic field committed to optimizing patient outcomes. While regulatory hurdles and safety concerns remain, ongoing research and comprehensive clinical trials are crucial for validating these emerging therapies and integrating them into standard practice.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial. (Pubmed Central) - Oct 15, 2024
P3
Assessing these parameters may help identify patients with heart failure with preserved ejection fraction at higher risk for adverse renal events and indicate potential therapeutic targets. URL: https://www.clinicaltrials.gov; Unique identifier: NCT01920711.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Qianyang Yuyin granules alleviate hypertension-induced vascular remodeling by inhibiting the phenotypic switch of vascular smooth muscle cells. (Pubmed Central) - Oct 12, 2024
URL: https://www.clinicaltrials.gov; Unique identifier: NCT01920711. QYYY may be able to inhibit the overactivation of the HIF-1?/TWIST1/P-p65 signaling pathway, improve the phenotypic switch, and balance apoptosis and autophagy in VSMCs, thereby effectively improving vascular remodeling caused by hypertension.